PASQUAZZI, Caterina
 Distribuzione geografica
Continente #
NA - Nord America 1.901
EU - Europa 618
AS - Asia 200
AF - Africa 14
SA - Sud America 9
Continente sconosciuto - Info sul continente non disponibili 1
OC - Oceania 1
Totale 2.744
Nazione #
US - Stati Uniti d'America 1.889
DE - Germania 251
IT - Italia 131
IN - India 87
SE - Svezia 71
SG - Singapore 48
CN - Cina 46
RU - Federazione Russa 43
UA - Ucraina 29
FI - Finlandia 27
IE - Irlanda 19
GB - Regno Unito 17
BG - Bulgaria 13
AR - Argentina 9
CA - Canada 8
RO - Romania 8
TG - Togo 8
HK - Hong Kong 7
MY - Malesia 5
BJ - Benin 4
BE - Belgio 3
BZ - Belize 2
CI - Costa d'Avorio 2
FR - Francia 2
IR - Iran 2
MX - Messico 2
TW - Taiwan 2
AU - Australia 1
BA - Bosnia-Erzegovina 1
EE - Estonia 1
EU - Europa 1
JP - Giappone 1
KZ - Kazakistan 1
LV - Lettonia 1
NL - Olanda 1
SA - Arabia Saudita 1
Totale 2.744
Città #
Fairfield 329
Ashburn 168
Woodbridge 162
Chandler 131
Houston 117
Cambridge 115
Seattle 115
Wilmington 104
Ann Arbor 86
Dearborn 71
Rome 48
Princeton 46
Plano 30
Beijing 26
San Paolo di Civitate 26
Lawrence 24
Singapore 21
Dublin 19
Boston 18
Millbury 18
San Diego 18
Jacksonville 14
Fremont 13
Sofia 13
Pune 11
Federal 9
Andover 8
Lomé 8
San Jose 8
Boardman 7
Helsinki 7
Hong Kong 7
Milan 6
Norwalk 6
Falls Church 5
New York 5
Phoenix 5
Bremen 4
Dallas 4
Fasano 4
Frankfurt am Main 4
San Mateo 4
Toronto 4
Brussels 3
Des Moines 3
Fiano Romano 3
Jinan 3
Mannheim 3
Nanchang 3
Ottawa 3
Quarrata 3
Washington 3
Abidjan 2
Albano Laziale 2
Belize City 2
Brescia 2
Bühl 2
Chicago 2
Delhi 2
Hefei 2
Redwood City 2
Tappahannock 2
Vittuone 2
Almaty 1
Atlanta 1
Auburn Hills 1
Buffalo 1
Catania 1
Chengdu 1
Columbus 1
Fuzhou 1
Grafing 1
Henderson 1
Jinhua 1
Kazan 1
Kilburn 1
Kunming 1
Lappeenranta 1
Leawood 1
London 1
Los Angeles 1
Messina 1
Mexico City 1
Miaoli 1
Montréal 1
Mostar 1
Nanjing 1
Nantong 1
Naples 1
Pars 1
Prescot 1
Quzhou 1
Riga 1
Ryazan 1
Sabaudia 1
Saint Louis 1
Shenyang 1
Southend 1
Stockholm 1
Taipei 1
Totale 1.934
Nome #
Helicobacter pylori active infection in patients with acute coronary heart disease 141
HCV NS3 sequencing as a reliable and clinically useful tool for the assessment of genotype and resistance mutations for clinical samples with different HCV-RNA levels 136
Multiclass HCV resistance to direct-acting antiviral failure in real-life patients advocates for tailored second-line therapies 134
A case report of pityriasis lichenoides in a patient with chronic hepatitis C. 113
Alpha-defensin increase in peripheral blood mononuclear cells from patients with hepatitis C virus chronic infection 110
Undetectable phospho-STAT1 in peripheral blood mononuclear cells from patients with chronic hepatitis C who do not respond to interferon-alpha therapy 99
Pegylated interferon alfa-2b plus ribavirin in the retreatment of interferon-ribavirin nonresponder patients 96
Safety and efficacy of ombitasvir/paritaprevir/ritonavir/dasabuvir plus ribavirin in patients over 65 years with HCV genotype 1 cirrhosis 90
Development of hepatotoxicity in HIV patients switching at least one protease inhibitor 87
Correlation of serum aminotransferases with HCV RNA levels and histological findings in patients with chronic hepatitis C: the role of serum aspartate transaminase in the evaluation of disease progression 82
Prevalence of single and multiple natural NS3, NS5A and NS5B resistance-associated substitutions in hepatitis C Virus Genotypes 1-4 in Italy 81
Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis (ABACUS): a prospective observational study 81
Hepatitis Delta Antigen (HDAg) is characterized by an extensive degree of genetic variability that correlates with elevated levels of serum HDV-RNA 80
Correlation of serum aminotransferases with HCV-RNA levels and histological findings in patients with chronic hepatitis C: the role of AST in the evaluation of disease progression 78
HDV can constrain HBV genetic evolution in hbsag: Implications for the identification of innovative pharmacological targets 77
METHODOLOGICAL ISSUES IN PAPERS ON IFN THERAPY: TIME FOR REAPPRAISAL 76
THU-117-Evaluation of risk factors associated with failure to a first-line NS5A-containing regimen in HCV-infected patients naive to direct acting antivirals: Particular focus on natural resistance 76
null 72
null 69
Antibody-selected mimics of hepatitis C virus hypervariable region 1 activate both primary and memory Th lymphocytes 68
In HBeAg-negative chronic HBV infection, HBsAg levels profoundly vary among different HBV-genotypes and can be influenced by the degree of HBsAg variability: can quantitative HBsAg truly reflect intra-hepatic HBV reservoir? 67
The circulation of specific vaccine-escape HBsAg mutations in HBV genotype D infected patients correlates with high viremia and affects HBsAg detection and quantification 66
HBV-HDV Co-Infection Constrains HBV Genetic Evolution in HBsAg 66
Dasabuvir and Ombitasvir/Paritaprevir/Ritonavir with or without Ribavirin in Patients with HIV-HCV Coinfection. Real Life Interim Analysis of an Italian Multicentre Compassionate Use Program 66
Liver cirrhosis: Epidemiological aspects in Italy 64
Trend of estimated glomerular filtration rate during ombistasvir/paritaprevir/ritonavir plus dasabuvir ± ribavirin in HIV/HCV co-infected patients 63
Ombitasvir/Paritaprevir/Ritonavir and dasabuvir combination treatment in patients with HIV/HCV co-infection: results of an italian compassionate use program 61
HCV INFECTION OF PERIPHERAL BLOOD MONONUCLEAR CELLS AND SERUM LEVELS OF SOLUBLE ICAM-1 IN PATIENTS TREATED WITH INTERFERON 58
HEPATITIS C VIRUS GENOTYPE, HEPATITIS C VIRUS RNA TITERS AND RESPONSE TO INTERFERON 54
null 52
The novel HBx mutation F30V correlates with hepatocellular carcinoma in vivo, reduces hepatitis B virus replicative efficiency and enhances anti-apoptotic activity of HBx N terminus in vitro 52
Hepatitis C virus RNA in peripheral blood mononuclear cells: relation with response to interferon treatment. 46
null 43
Frequent NS5A and multiclass resistance in almost all HCV genotypes at DAA failures: What are the chances for second-line regimens? 43
Novel HBsAg mutations correlate with hepatocellular carcinoma, hamper HBsAg secretion and promote cell proliferation in vitro 42
Serum concentration of gammaGT is a surrogate marker of hepatic TNF-alpha mRNA expression in chronic hepatitis C 37
Resistance analysis and treatment outcomes in hepatitis C virus genotype 3-infected patients within the Italian network VIRONET-C 33
Unexpected rise in the circulation of complex hbv variants enriched of hbsag vaccine-escape mutationshbvn HB genotype-d. Potential impact on hbsag detection/quantification and vaccination strategies 20
Characterization of baseline factors associated with treatment outcome in HCV-infected patients naive to direct acting antivirals: particular focus on natural resistance 20
Characterization of resistance profiles in HCV 2-3-4 DAA-naïve and DAA-experienced infected patients in Italy 17
In the ERA of New Direct Acting Antiviral Agents HCV Sequencing Allows the Most Accurate Subtype and Genotype Assignment 15
Improvement of ALT decay kinetics by all-oral HCV treatment: Role of NS5A inhibitors and differences with IFN-based regimens 14
Optimal efficacy of interferon-free HCV retreatment after protease inhibitor failure in real life 12
Key mutations in the C-terminus of the HBV surface glycoprotein correlate with lower HBsAg levels in vivo, hinder HBsAg secretion in vitro and reduce HBsAg structural stability in the setting of HBeAg-negative chronic HBV genotype-D infection 7
null 6
null 5
Genetic Determinants in a Critical Domain of NS5A Correlate with Hepatocellular Carcinoma in Cirrhotic Patients Infected with HCV Genotype 1b 4
Totale 2.879
Categoria #
all - tutte 7.112
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 7.112


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020758 0 37 16 42 99 128 119 92 95 75 30 25
2020/2021251 29 30 10 9 1 27 3 13 26 56 28 19
2021/2022468 10 20 31 15 51 11 9 41 51 23 127 79
2022/2023437 85 84 22 51 50 38 1 32 42 7 16 9
2023/2024224 21 30 14 16 18 35 8 25 0 32 10 15
2024/202518 15 3 0 0 0 0 0 0 0 0 0 0
Totale 2.879